Table 2.
Efficacy data.
| T0 | T1 | T3 | T6 | P-value | |
|---|---|---|---|---|---|
| Platelet count, × 109/L | 10 | 34 | 42 | 92 | <0.0001 |
| Median (range) | (1–51) | (1–668) | (1–703) | (2–863) | |
| Patients with a platelet count of at least 30 × 109/L, n°/TOT (%) | 12/71 (17) | 40/71 (56) | 40/68 (56) | 39/57 (68) | <0.0001 |
| Patients with a platelet count of at least 100 × 109/L, n°/ TOT (%) | 0/71 (0) | 10/71 (14) | 10/68 (15) | 25/57 (44) | <0,0001 |
Median platelet count (× 109/L), percentage of patients with a platelet count ≥30 × 109/L, percentage of patients with a platelet count ≥100 × 109/L at the start of therapy (T0); after 1 month (T1); after 3 months (T3); after 6 months (T6).